Search clinical trials for: Vorapaxar 2.08 mg/d background APT SMT.

Total 7 results

North Texas Veterans Healthcare System

Unknown

Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) (XLPADTRACE)

Peripheral Arterial Disease

United States
Merck Sharp & Dohme LLC

Completed

Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)

Cerebral Infarction
Merck Sharp & Dohme LLC

Completed

Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672) (VICTOR-E1)

HIV Infections
University of Cologne

Terminated

Efficacy of Hybrid Systems in Comparison to the Rigid Spondylodesis in Lumbar-spine Fusion (D-Rod)

Spondylolisthesis

Germany
Amsterdam Molecular Therapeutics
International Antiviral Therapy Evaluation Center

Unknown

Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]

Familial Lipoprotein Lipase Deficiency

Canada
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

Recurrent Neuroblastoma | Refractory Neuroblastoma | High Risk Neuroblastoma

United States, Canada, Puerto Rico, Australia, New Zealand
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia

United States

3

Subscribe